ArticleVaccine2015
Rescue of a vaccine strain of peste des petits ruminants virus: In vivo evaluation and comparison with standard vaccine.
Article in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Developments in Negative-Strand RNA Virus Reverse Genetics.Microorganisms · 2024Review
- Reverse Genetics Systems for the De Novo Rescue of Diverse Members of Paramyxoviridae.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The evaluation of five serological assays in determining seroconversion to peste des petits ruminants virus in typical and atypical hosts.Scientific reports · 2023Article
- Article
- Assessment of the control measures of the category A diseases of Animal Health Law: peste des petits ruminants.EFSA journal. European Food Safety Authority · 2021Article
- Review
- A New Look at Vaccine Strategies Against PPRV Focused on Adenoviral Candidates.Frontiers in veterinary science · 2021Review
- Inhibition of eIF2α Phosphorylation by Peste des Petits Ruminant Virus Phosphoprotein Facilitates Viral Replication.Frontiers in veterinary science · 2021Article
- Full genome sequencing of archived wild type and vaccine rinderpest virus isolates prior to their destruction.Scientific reports · 2020Article
- Article
- Expression and characterization of the non-structural protein V of small ruminant morbillivirus.Virusdisease · 2019Article
- Review
- Article
- Monoclonal antibody resistant mutant ofVirusdisease · 2018Article
- Reverse Genetics for Peste des Petits Ruminants Virus: Current Status and Lessons to Learn from Other Non-segmented Negative-Sense RNA Viruses.Virologica Sinica · 2018Review
- Future research to underpin successful peste des petits ruminants virus (PPRV) eradication.The Journal of general virology · 2017Review
- Advances in peste des petits ruminants vaccines.Veterinary microbiology · 2017Review
- Peste des petits ruminants.Veterinary microbiology · 2015Review
- Peste des petits ruminants vaccine and vaccination in India: sharing experience with disease endemic countries.Virusdisease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Across the developing world peste des petits ruminants virus places a huge disease burden on agriculture, primarily affecting the production of small ruminant. The disease is most effectively controlled by vaccinating sheep and goats with live attenuated vaccines that provide lifelong immunity. However, the current vaccines and serological tests are unable to enable Differentiation between naturally Infected and Vaccinated Animals (DIVA). This factor precludes meaningful assessment of vaccine coverage and epidemiological surveillance based on serology, in turn reducing the efficiency of control programmes. The availability of a recombinant PPRV vaccine with a proven functionality is a prerequisite for the development of novel vaccines that may enable the development of DIVA tools for PPRV diagnostics. In this study, we have established an efficient reverse genetics system for PPRV Nigeria 75/1 vaccine strain and, further rescued a version of PPRV Nigeria 75/1 vaccine strain that expresses eGFP as a novel transcription cassette and a version of PPRV Nigeria 75/1 vaccine strain with mutations in the haemagglutinin (H) gene to enable DIVA through disruption of binding to H by the C77 monoclonal antibody used in the competitive (c) H-ELISA. All three rescued viruses showed similar growth characteristics in vitro in comparison to parent vaccine strain and, following in vivo assessment the H mutant provided full protection in goats. Although the C77 monoclonal antibody used in the cH-ELISA was unable to bind to the mutated form of H in vitro, the mutation was not sufficient to enable DIVA in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.